Latest Oncology News

Combining Camrelizumab, Chemotherapy Leads to Survival Benefit in Esophageal Squamous Cell Carcinoma

July 23, 2021

The frontline combination of camrelizumab and chemotherapy resulted in improved overall survival and progression-free survival and a manageable safety profile compared with placebo plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.

Overall Survival Results of I/O Combinations Differ Across Risk Groups of Metastatic RCC

July 22, 2021

The overall survival benefit of immunotherapy combinations compared with sunitinib for the treatment of patients with metastatic renal cell carcinoma who have favorable risk may differ from those who have intermediate or poor risk, according to a pooled analysis of frontline combination therapy conducted by the FDA.

Survival in Advanced ESCC Improved With Frontline Nivolumab Plus Ipilimumab or Chemotherapy

July 22, 2021

Improved survival outcomes were reported with the addition of nivolumab to either ipilimumab or chemo-therapy vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or meta-static esophageal squamous cell carcinoma.

Venugopal Considers BTK and BCL2 Inhibitors in Patient With CLL

July 22, 2021

Treatment for a patient with chronic lymphocytic leukemia who has comorbidities including hypertension and atrial fibrillation was the topic of discussion during a Targeted Oncology Case-Based Roundtable event led by Parameswaran Venugopal, MD.

FDA Approves Lenvatinib/Pembrolizumab for Select Patients With Advanced Endometrial Cancer

July 22, 2021

The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair deficient, who have disease progression following prior systemic treatment and who are not candidates for curative surgery or radiation.

Tafasitamab/Lenalidomide Combo Demonstrates Favorable Efficacy in DLBCL

July 21, 2021

In the case that a clinical trial is not an option for a 75-year-old male patient with diffuse large B-cell lymphoma who is ineligible for transplant due to older age and high risk. Herbert A. Eradat, MD, explains his treatment plan.